Ad
CNCE - Concert Pharmaceuticals Stock Trading
About | Concert Pharmaceuticals Inc. (NASDAQ:CNCE)
Not available
Quote | Concert Pharmaceuticals Inc. (NASDAQ:CNCE)
| Last: | $8.37 |
|---|---|
| Change Percent: | -0.12% |
| Open: | $8.38 |
| Close: | $8.37 |
| High: | $8.55 |
| Low: | $8.35 |
| Volume: | 10,733,298 |
| Last Trade Date Time: | 03/03/2023 03:00:00 am |
News | Concert Pharmaceuticals Inc. (NASDAQ:CNCE)
-
Summary Concert Pharmaceuticals, Inc. is a biotech buyout trading at a negative spread but with an interesting CVR attached. The CVR is based on two sales milestones. The 1st milestone appears quite achievable. The 2nd milestone can be considered a "free" option. Conce...
-
Concert Pharmaceuticals ( NASDAQ: CNCE ) announced Wednesday that the FDA allowed the company to keep its Breakthrough Therapy Designation for hair loss therapy deuruxolitinib, despite the agency’s approval of a rival therapy. In 2020, the FDA initially issued Breakthrough Ther...
Message Board Posts | Concert Pharmaceuticals Inc. (NASDAQ:CNCE)
| Subject | By | Source | When |
|---|---|---|---|
| Sun Pharma Completes Acquisition of Concert Pharmaceuticals (3/06/23) | Enterprising Investor | investorshub | 03/06/2023 2:22:56 PM |
| whytestocks: $CNCE News Article - CNCE Stock Alert: Halper Sadeh LLC is Investigating Whether the Sa | whytestocks | investorshangout | 01/19/2023 3:35:44 PM |
| whytestocks: $CNCE News Article - Concert Pharmaceuticals to Present at H.C. Wainwright Global Inves | whytestocks | investorshangout | 09/06/2022 12:35:57 PM |
| whytestocks: $CNCE News Article - Concert Pharmaceuticals Announces Exercise of Warrants Under Exist | whytestocks | investorshangout | 08/22/2022 12:35:59 PM |
| whytestocks: $CNCE News Article - Concert Pharmaceuticals Reports Positive Topline Results for Secon | whytestocks | investorshangout | 08/01/2022 12:15:55 PM |
News, Short Squeeze, Breakout and More Instantly...
Concert Pharmaceuticals Inc. Company Name:
CNCE Stock Symbol:
NASDAQ Market:
Concert Pharmaceuticals Inc. Website:
Ad
-
Concert Pharmaceuticals, Inc. today announced that, after a recent review of deuruxolitinib clinical data by the U.S. Food and Drug Administration (FDA), the FDA determined that deuruxolitinib will maintain its Breakthrough Therapy designation. Deuruxolitinib, an oral Janus kinase (JAK) inhibit...
-
NEW YORK, NY / ACCESSWIRE / January 24, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Concert Pharmaceuticals, Inc. (NASDAQ...
-
If all goes according to plan, Concert Pharmaceuticals (NASDAQ: CNCE) will soon cease to be an independent company. The biotech signed a deal to be acquired by a peer; as a result, its share price leaped more than 17% higher on the week, according to data compiled by S&P Global Mark...